Rpo LLC Invests $42,000 in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Rpo LLC bought a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 66,378 shares of the company’s stock, valued at approximately $42,000.

A number of other institutional investors also recently modified their holdings of the stock. Centiva Capital LP acquired a new stake in Lyell Immunopharma in the third quarter worth $31,000. Intech Investment Management LLC bought a new position in shares of Lyell Immunopharma during the 3rd quarter worth about $52,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at about $52,000. SG Americas Securities LLC increased its position in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after buying an additional 59,182 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $0.51 on Thursday. The stock has a market cap of $149.83 million, a price-to-earnings ratio of -0.64 and a beta of -0.41. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The firm’s 50-day simple moving average is $0.61 and its 200 day simple moving average is $0.85.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.01 million during the quarter. On average, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, CFO Charles W. Newton bought 200,000 shares of Lyell Immunopharma stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 200,000 shares in the company, valued at approximately $112,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Lynn Seely purchased 175,000 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the transaction, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at $434,625. The trade was a 32.56 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 768,640 shares of company stock worth $449,508. Corporate insiders own 25.10% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.